Compass Pathways Shares Jump After Second Positive Phase 3 Readout for COMP360
Compass Pathways Plc saw its stock surge after reporting statistically significant results from its second Phase 3 trial of COMP360, a synthetic psilocybin therapy for treatment-resistant depression. The COMP006 study met its primary endpoint with the 25mg dose producing a meaningful reduction on the MADRS scale versus the 1mg control, with rapid o…